Antares Pharma (Antares Pharma) EV-to-EBITDA : 14.93 (As of May. 04, 2024)

Antares Pharma EV-to-EBITDA Chart

Antares Pharma Annual Data
	Trend	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21
EV-to-EBITDA		Get a 7-Day Free Trial					-23.08	-386.81	190.71	40.37	8.10

Antares Pharma Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
EV-to-EBITDA	Get a 7-Day Free Trial															29.40	26.68	19.78	8.10	10.77

Competitive Comparison of Antares Pharma's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Antares Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antares Pharma's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Antares Pharma's EV-to-EBITDA falls into.

Antares Pharma EV-to-EBITDA Calculation

Antares Pharma's EV-to-EBITDA for today is calculated as:

Antares Pharma's current Enterprise Value is $918.3 Mil.
Antares Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $61.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antares Pharma  (NAS:ATRS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Antares Pharma's PE Ratio for today is calculated as:

Antares Pharma's share price for today is $5.59.
Antares Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Antares Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Antares Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Antares Pharma (Antares Pharma) Business Description